News & Events
Crinetics Pharmaceuticals Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Crinetics today announced the closing of its initial public offering of 6,900,000 shares of common stock, which includes the exercise in full of the underwriters' option to purchase 900,000 additional shares of common stock, at a public offering price of $17. 00 per share. The aggregate gross proceeds to Crinetics from the offering were $117.
READ MORECrinetics Pharmaceuticals Announces Pricing of Initial Public Offering
Crinetics today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $17. 00 per share. All of the shares are being offered by Crinetics.
READ MORECrinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly
Crinetics Pharmaceuticals, Inc. , today announced that it has been awarded up to approximately $3. 2 million in Small Business Innovation Research (SBIR) grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to fund the continued research and development of its nonpeptide, oral somatostatin agonists for congenital hyperinsulinemias (CHI) and acromegaly.
READ MORECrinetics Pharmaceuticals Appoints Alan Krasner, M.D., as Chief Medical Officer
Crinetics Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Alan S. Krasner, M.
READ MORETop News: Crinetics raises $63.5 million in new funds and adds to BOD
Crinetics has completed a $63. 5 million Series B financing to continue development of its lead product for acromegaly and other new therapeutics targeting rare endocrine disorders.
READ MORECrinetics Pharmaceuticals Completes $63.5 Million Series B Financing
The investment was led by Perceptive Advisors and includes new investors RA Capital and OrbiMed. Existing investors 5AM Ventures, Versant Ventures and Vivo Capital participated in the financing as well. Crinetics Pharmaceuticals plans to use the proceeds to fund the continuing development of CRN00808, an oral nonpeptide somatostatin agonist for the potential treatment of acromegaly, to develop additional new targeted therapeutics for endocrine disorders and endocrine related cancers, and for general corporate purposes.
READ MORECrinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
SAN DIEGO – March 12, 2018 – Crinetics Pharmaceuticals, Inc. , a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an oral presentation and two poster presentations relating to the company’s drug development candidates. These presentations will be made at the upcoming ENDO 2018, the Annual Meeting of the Endocrine Society, taking place from March 17-20, 2018 in McCormick Place West, Chicago, Illinois.
READ MORECrinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
Crinetics Pharmaceuticals, Inc. , a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph. D.
READ MORECrinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer
SAN DIEGO – January 4, 2018 – Crinetics Pharmaceuticals, Inc. , a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced the appointment of Marc Wilson to the executive team as Chief Financial Officer.
READ MORECrinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
SAN DIEGO – January 2, 2018 – Crinetics Pharmaceuticals, Inc. , a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph. D.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
